NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage innovator in broad-spectrum antivirals, announced near-finalization of its adaptive clin ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

The Director-General of the World Health Organization (WHO) is hereby transmitting the report of the fourth meeting of the International Health Regulations (2005) (IHR) Emergency Committee (Committee) ...

NanoViricides, Inc. is a publicly traded clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. The company's innovative nanoviricide class of drug candidates ...

An analysis of mpox virus genomes from individuals infected between 2018 and 2023 has provided insights into how the virus ...

The Philippine Society for Microbiology and Infectious Diseases (PSMID) on Monday said that all mpox cases in the country remain part of Clade 2, with no detection of the more severe Clade 1b strain ...

ATLANTA, GA - February 19, 2025 (NEWMEDIAWIRE) - The confirmation of a fourth case of Clade 1 Mpox in New York underscores the urgent need for a stronger and more diversified vaccine supply chain.

The GREAT-LIFE project is behind both the discovery of clade 1b and the development of a new PCR test, which enables the detection of clade 1b—undetectable by the original mpox tests.

The New York State Department of Health has issued a health advisory following the detection of the first mpox clade Ib case in New York State.